Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gallbladder Adenocarcinoma: early-phase trial registry
3 of 4 indexed Gallbladder Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Gallbladder Adenocarcinoma: 4 US clinical trials tracked, 3 recruiting.
Gallbladder Adenocarcinoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Georgetown University, running 1 of these trials.
Enrollment posture brief
Registry condition gallbladder-adenocarcinoma
OPEN 3 | RECR 75% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Gallbladder Adenocarcinoma lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gallbladder Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gallbladder Adenocarcinoma is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Yale University
NCT07282912
Evaluating Novel Therapies in ctDNA Positive GI Cancers
Georgetown University
NCT05482516
Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma
West Virginia University
NCT05430035
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
Massachusetts General Hospital
NCT00142480
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Gallbladder Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gallbladder Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gallbladder Adenocarcinoma page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Gallbladder Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Georgetown University sponsors the most Gallbladder Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Georgetown University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gallbladder Adenocarcinoma condition card totals 4 registered trials; most-linked intervention Bevacizumab; top US site state West Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.